[Prostate cancer - diagnostics and screening]. : Prostatacancer – utredning, klinisk diagnostik och screening.

• Prostate-specific antigen (PSA) based screening is controversial, even though randomised trials show that screening can reduce prostate cancer mortality. The main reason is that screening leads to overdiagnosis of indolent cancers that would never have surfaced clinically in the absence of screening. Recently, several large studies have shown that magnetic resonance imaging (MRI) improves prostate cancer diagnostics. With MRI, up to half of all men with elevated PSA values can be spared a biopsy. When a biopsy is needed, the needles can be directed towards the suspicious area in the prostate, which increases the detection of clinically significant tumors. In Sweden, regional programmes with organised prostate cancer testing were introduced in 2020. These programmes aim to make prostate cancer testing more standardized, efficient, and equitable. In the future, biomarkers and AI-based systems will likely be important to further improve prostate cancer diagnostics.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Urology and Nephrology (hsv//eng)

Nyckelord

Humans

Prostatic Neoplasms

diagnosis

blood

Male

Prostate-Specific Antigen

blood

Early Detection of Cancer

Magnetic Resonance Imaging

Sweden

Mass Screening

Biopsy

Biomarkers

Tumor

blood

analysis

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)